PTAB

The USPTO Appeals Review Panel reinstated all OTDP rejections, holding that Federal Circuit precedent makes the anti-harassment rationale independently sufficient even without patent-term extension.

The Patent Trial and Appeal Board cancels all eight claims of Intellectual Ventures’ U.S. Patent 11,664,889, which covers TD-CDMA closed-loop power control in 3G wireless networks, finding them unpatentable over prior art combinations led by the Dateki reference.

The Patent Trial and Appeal Board issued a split final written decision in a pair of inter partes review proceedings filed by ResMed Corp., finding one Cleveland Medical Devices sleep apnea treatment patent unpatentable while upholding claims in a closely related companion patent, illustrating the a

A PTAB leadership panel on June 26, 2026 reversed the Board’s earlier cancellation of an Express Mobile website-building patent, holding that PTAB should not reach a different validity outcome than the jury when both forums consider the same evidence — a ruling with broad implications for GoDaddy’s

The PTAB held that a child patent in a continuation family is not invalid for obviousness-type double patenting (ODP) if its expiration date does not exceed the original patent’s expiration date — including any patent term adjustment (PTA) — providing important clarity for continuation patent strate

USPTO Director John Squires vacated a PTAB panel’s obviousness finding on U.S. Patent No. 11,828,425, ruling the Board failed to explain why its conclusion on claim 2 differed from a jury verdict finding the same claim valid and infringed — reinforcing the September 2025 PTAB parallel-proceedi

USPTO Director Squires issued a precedential decision vacating three IPR institution grants after a federal court found all challenged Lightning Roulette patents invalid under § 101, while simultaneously establishing a new 30-day deadline for parties to request Director Review of institution decisio

A new PTAB panel — assembled after a conflict-of-interest controversy forced removal of the original APJ — issues a second Final Written Decision finding U.S. Patent No. 9,917,856 unpatentable on obviousness grounds, dealing another blow to Centripetal Networks’ once-$1.9 billion patent assert

The Patent Trial and Appeal Board upheld two Zaxcom wireless audio recording patents in back-to-back IPR final written decisions, finding that Academy Award and Emmy Award recognition for the technology defeated RØDE Microphones’ obviousness challenge.

The Patent Trial and Appeal Board invalidated all claims of Inari Medical’s U.S. Patent No. 11,554,005 covering a system for treating embolism, finding the claims anticipated by and obvious over prior art in a Final Written Decision from IPR2025-00289.

The Patent Trial and Appeal Board issued split decisions in Stratasys Inc.’s ongoing patent dispute with Chinese 3D-printing rival Bambu Lab and its parent Shenzhen Tuozhu Technology, invalidating claims in one Stratasys patent while upholding another covering networked 3D printing.

The Patent Trial and Appeal Board invalidated all claims of Inari Medical’s U.S. Patent No. 11,554,005 covering a system for treating embolism, finding the claims anticipated by and obvious over prior art in a Final Written Decision from IPR2025-00289.

The Patent Trial and Appeal Board issued split decisions in Stratasys Inc.’s ongoing patent dispute with Chinese 3D-printing rival Bambu Lab and its parent Shenzhen Tuozhu Technology, invalidating claims in one Stratasys patent while upholding another covering networked 3D printing.

The PTAB issues a Final Written Decision upholding Yangtze Memory Technologies’ U.S. patent on electrostatic discharge bus architecture, rejecting Micron’s invalidity challenge — and earlier rejecting Micron’s novel argument that national security grounds should shield the IPR from